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Introduction
In general, hemolytic transfusion reactions (HTRs) are well 
characterized by their occurrence in association with blood trans-
fusion. Key serological findings are predominantly detectable al-
loantibodies in serum samples of affected patients and, to a varia-
ble extent, a positive direct antiglobulin test (DAT) occurring in 
association with or without clinical or laboratory signs of hemoly-
sis (clinical HTR or serological HTR). In comparison, autoimmune 
hemolytic anemias (AIHA) are characterized by their clinical pic-
tures, a positive DAT, and in cases of warm-type AIHA by autoan-
tibodies, which are predominantly detectable on patients’ red 
blood cells (RBCs) and to a lesser degree as free antibodies in the 
serum [1–3]. However, the results of serological findings in HTRs 
are variable and may result in confusion. Often they are dependent 
on numerous factors such as the causative antibodies, the amount 
of transfused RBCs, the time interval between the last transfusion 
and testing, and the methods applied for analysis. Here, we report 
on a patient with intriguing serological findings, which resulted in 
incompatible blood transfusions and life-threatening hemolysis. 
Material and Methods
Indirect antiglobulin test (IAT) and DAT were performed using the stan-
dard gel technique (Bio-Rad, Cressier sur Morat, Switzerland). All anti-immun-
globulin (Ig) reagents used were from commercial sources: anti-IgG, anti-IgA, 
anti-IgM (Bio-Rad Medical Diagnostics, Dreieich, Germany) and anti-C3d 
(Dako, Hamburg, Germany). Eluate from the patient’s RBCs was prepared 
using the acid method (BAG, Lich, Germany). Serum and eluate IAT tests were 
performed using polyspecific Ig cards, and neutral gel cards were used for two-
stage enzyme technique (BioRad). For differentiation of Anti-c und Anti-D, 
rare RBCs (Rh null, CCddee) from in-house library were used. Auto anti-LW 
was considered, but LW-negative, D-positive and c-negative RBCs were not 
available for testing.
Blood group antigens for D, C, E, c, and e were determined by hemaggluti-
nation in gel cards using monoclonal reagents (BioRad) or by automated mi-
croplate technique (Galileo Immucor, Norcross, GA, USA). Genotyping for 
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Summary
Background: The phenomena of co-incidence of transfu-
sion-induced allo- and autoantibodies, blockage and/or 
loss of red blood cell (RBC) antigens are conspicuous and 
may result in confusion and misdiagnosis. Case Report: 
A 67-year-old female was transferred to the intensive 
care unit due to hemolysis which developed 2 days fol-
lowing transfusion of three Rh(D)-negative RBC units in 
the presence of strongly reactive autoantibodies. Stand-
ard serological testing and genotyping were performed. 
Upon arrival, the patient was typed as Ccddee. Her he-
molysis was decompensated, and an immediate blood 
transfusion was required. In addition, direct and indirect 
antiglobulin tests (DAT and IAT) as well as the eluate 
were strongly positive. Emergency transfusion of Rh(D)-
negative RBCs resulted in increased hemolysis and renal 
failure. An exhaustive testing revealed anti-D, anti-c, CCd-
dee phenotype and CCD.ee genotype. Three units of cryo-
preserved CCddee RBCs were transfused, and the pa-
tient’s condition immediately improved. The discrepancy 
between Rh-D phenotyping and genotyping was likely 
caused by masking of the D-epitopes by the autoantibod-
ies. In fact, further enquiry revealed that the patient had 
been phenotyped as Rh(D)-positive 6 months ago and 
had been transfused at that time following hip surgery. 
Conclusion: The phenomena of transfusion-induced au-
toantibodies, masked alloantibodies, antigen blockage 
and/or loss are rare but important features which should 
be considered in patients presenting with autoimmune 
hemolytic anemia and/or hemolytic transfusion reactions. 
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RHD and RHCE was performed after DNA extraction using PCR-SSP (BAG 
and Inno-train, Kronberg, Germany, respectively) and exon sequencing of RHD 
gene. 
Case Report
A 67-year-old woman, with a history of hip surgery and blood transfusion 
(three O CcDee and one O ccDee) 6 months previously, was re-admitted to 
hospital for total hip replacement surgery (fig. 1). During this procedure, an ur-
gent blood transfusion was required due to significant blood loss. Though the 
patient was typed as O Rh(D)-positive prior to the first hip replacement, retyp-
ing revealed CCddee. However, the DAT and antibody screen test were strongly 
positive, leading to the assumption that a positive Coombs cross-match of 
RBCs, prepared for perisurgery blood demand, was related to a high-titer au-
toantibody. No signs of hemolysis were present, and three cross-match-positive 
Rh(D)-negative (ccddee) RBC units were transfused during surgery. The pa-
tient developed a delayed hemolytic transfusion reaction 2 days posttransfusion 
and was transferred to the intensive care unit (ICU) at the university hospital. 
On arrival, hemolysis was decompensated (hemoglobin concentration 6.4 g/dl 
(reference range 11.9–16.1 g/dl), lactate dehyrogenase 1,248 U/l (reference 
range < 250 U/l) , haptoglobin <0.08 g/l (reference range 0.3–2.0 g/l), free 
hemoglobin in plasma 27 μmol/l (reference range 0–10 μmol/l), creatinine 351 
μmol/l (reference range 42–80 μmol/l) and indirect bilirubin 169.6 μmol/l (ref-
erence range 0–17 μmol/l)) requiring further emergency blood transfusions. 
Results
Serological examination revealed blood group type O Ccddee, 
strong positive DAT (anti-IgG 4+ and anti-C3d 1+) and panagglu-
tinating IAT using both serum and eluate samples. AIHA was sus-
pected, and treatment with steroids (100 mg/day prednisolone) 
commenced. The patient subsequently received 8 units of O 
Rh(D)-negative RBCs over the span of 6 days. Clinical signs of 
acute hemolytic reactions, e.g. back pain, were not observed, prob-
ably due to persistent hemolysis and treatment with steroids. He-
molysis could not be halted, and the patient required hemodialysis 
due to renal failure. Subsequent examinations, including testing of 
rare RBCs, revealed in parallel the phenotype CCddee, anti-D, 
anti-c, and genotype CCD.ee (including sequencing). Three units 
of cryopreserved CCddee RBCs were transfused; the patient’s 
hemoglobin concentration increased from 4.5 to 6.7 g/dl and he-
molysis gradually abolished (fig.  2). Control testing following a 
time span of 6 weeks demonstrated phenotype O CCD.ee, anti-c, 
anti-S, strong positive DAT and panagglutinating eluate. Three 
months later, serological re-examination confirmed blood group O 
CCD.ee. In addition, anti-E was detectable in the patient’s serum, 
and the DAT was strongly positive due to auto-anti-D (fig. 1).
Discussion
The patient described here demonstrates various intriguing se-
rological findings, which resulted in confusion and HTR. The pa-
tient was admitted to the ICU, blood transfusion was urgently re-
quired, and no cross-match-compatible RBCs were available. At 
this time the true rhesus antigens were unknown due to prior 
transfusions, the true diagnosis was unclear, and blood samples for 
extensive testing were limited due to significant hypoxic anemia. In 
this scenario the risk of severe morbidity and a fatal outcome due 
to hypoxemia had to be balanced against the risk of incompatible 
blood transfusion. The DAT was strongly positive prior to the first 
perisurgical transfusion and the hemolytic attack. This led to the 
following considerations:
The patient may have AIHA of warm type, which exacerbated 
due to blood transfusion. Consequently a treatment with steroids 
was commenced.
The patient may have a HTR due to autoantibodies with a con-
comitant antibody directed against a high-frequency antigen. Ulti-
mately, the causative antibodies were a combination of auto-anti-D 
and anti-c, which gave homogeneous reactions with all normal RBCs. 
This reaction pattern is usually typical for the presence of an anti-
body directed against a high-frequency antigen. In this case, incom-
patible transfusion would be acceptable in order to save the patient’s 
life as long as the causative alloantibody could not be identified. 
Fig. 1. Patient’s course, serological findings, result of genotyping and treatment. 
BG = blood group; 4+ = Degree of reactivity (very strong); panagglut. = panag-
glutinating antibody; ab diff = antibody differentiation; Pred = prednisolone. 
Sümnig/Mayer/Kiefel/Greinacher/SalamaTransfus Med Hemother 2015;42:340–343342
The patient must have developed a HTR due to masked alloan-
tibodies. This scenario was surrounded by various interesting sero-
logical findings including the development of autoantibodies fol-
lowing blood transfusion, Rh(D) blocked phenomenon, masked 
anti-c, and false-positive c-phenotyping due to the transfused 
RBCs. All these phenomena are worth to be discussed further.
The occurrence of autoantibodies following blood transfusion 
has been described approximately 30 years ago [4]. Most intrigu-
ingly, these autoantibodies seem to persist for a long period of time 
without evidence of hemolysis. In the presented case, the most likely 
trigger for induction of autoantibodies was the blood transfusion 
during the first hip replacement surgery. Although the phenomenon 
of blood transfusion-induced autoantibodies has been supported by 
other groups [5, 6], it remains rather confusing in many cases. 
While the presence of RBC alloantibodies in patients with 
AIHA is well known among transfusion laboratory personnel, the 
induction of autoantibodies by blood transfusion is less known. It 
has been shown that the co-incidence of alloantibodies and au-
toantibodies in ‘true’ AIHA is less common than that of autoanti-
bodies and alloantibodies following hemolytic or non-hemolytic 
transfusion reactions [7, 8]. This indicates, that the co-incidence of 
autoantibodies and alloantibodies reflect hemolytic or non-hemo-
lytic transfusion reactions rather than AIHA.
The patient presented here appeared to had developed a potent 
auto-anti-D that resulted in the so-called blocked Rh(D) phenom-
enon. This phenomenon has been described in newborn hemolytic 
disease [9–11] and by the use of murine monoclonal antibodies 
[12–14]. To our knowledge, this is the first report describing this 
phenomenon in AIHA and serological transfusion reactions. 
The question why transfusion-induced autoantibodies remain 
detectable for a long time and do not cause significant hemolysis is 
obscure. 
A further potential scenario was that the patient had a variant 
Rh(D) antigen and had developed an alloantibody against unex-
pressed epitopes on autologous RBCs. This hypothesis was some-
what supported by the fact that isolated patients with Rh(D) vari-
ants may develop strong anti-D [15–17]. This hypothesis was later 
excluded by the results obtained from genotyping.
On admission to ICU, rhesus c antigen was detectable on circu-
lating RBCs (fig. 1). This was likely caused by the c-positive RBCs 
transfused 2 days earlier during surgery. Surprisingly, there was no 
evidence for the presence of mixed field agglutination. Subse-
quently transfused cells appeared to have lost c antigen as the pa-
tient was phenotyped CCee 6 days later. Antigen loss from anti-
body-coated RBCs has been described in patients with AIHA and 
HTR as well as in animal experiments [18–20]. Alternatively, c an-
tigen became coated by patient’s allo-anti-c, resulting in the anti-
gen-blocked phenomenon. A third explanation might be that the 
transfused c-positive RBCs were destroyed. 
In summary, although this case was rather complicated, further 
knowledge concerning the phenomena described here would be 
helpful in the management of such patients.
The remaining two major discussion points pertain firstly to the 
question whether or not masked alloantibodies would indeed cause 
massive HRT in patients with true AIHA, which is evidently rele-
vant, since these patients already have a limited hemolytic capacity 
due to the ongoing hemolysis. Secondly, how anucleated cells are 
able to lose their antigen following reactions with corresponding 
antibodies, remains ambiguous. 
Disclosure Statement
The authors declare no conflicts of interest.
Fig. 2. Course of RBC transfusion, hemoglobin 
(reference range 11.9–16.1 g/dl), creatinine (refer-
ence range 42–80 μmol/l), and bilirubin (reference 
range 0–17 μmol/l).
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